• Network Genomic Medicine
  • CIO Cologne Bonn
  • Contact
  • Imprint
  • Privacy Policy
  • English
    • Deutsch
Lung Cancer Group Cologne
  • Who we are
    • Aims
    • Study coordination
    • Team
  • Publications
    • Publications
    • Projects
  • Molecularpathology
    • For patients
    • Molecular Testing
    • Translational Genomics
  • Cologne Conference on Lung Cancer
  • Overview
  • Immunotherapy Trials
Select Page

Developments in oncological positron emission tomography/computed tomography assessment

by Sonja Köhler | Dec 7, 2015

Developments in oncological positron emission tomography/computed tomography assessment Kobe C, Boellaard R, Wolf J, Kuhnert G, Dietlein M, Neumaier B, Drzezga A, Kahraman D Journal: J Thorac Dis Veröffentlichung: 7. Dezember...

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases

by Sonja Köhler | Nov 6, 2015

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases. Meder L, König K, Fassunke J, Ozretić L, Wolf J, Merkelbach-Bruse S, Heukamp LC, Buettner R. Journal: Exp Mol Pathol Veröffentlichung: 6. November...

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

by Sonja Köhler | Oct 18, 2015

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M Journal: Oncologist Veröffentlichung: 20....

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

by Sonja Köhler | Oct 10, 2015

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, T Buhl, Hartmann W, Wolf J, Merkelbach-Bruse S, M...

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

by Sonja Köhler | Sep 4, 2015

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, T Buhl, Hartmann W, Wolf J,...
« Older Entries

Find study

  • Genmutation (Marker)

Suche

News-Kategorien

  • Uncategorized (1)

Aktuelle Beiträge

  • SAVE THE DATE: 2nd Cologne Conference on Lung Cancer

The LCGC study center team, led by prof. Juergen Wolf, is located at Dept. I of Internal Medicine in the Center for Integrated Oncology at the University Hospital Cologne. Our goal is to achieve an effective treatment for patients with lung cancer.
For this purpose we are developing our own study reports for treating genetically defined subgroups of lung cancer and to optimize immunotherapy. We do this in close cooperation with the work groups in translational cancer genomics, molecular pathology and molecular imaging.

„NGMCIO Köln BonnUniklinik Köln

Ansprechpartner & Kontaktdaten

Universitätsklinik Köln (AöR)
Klinik I für Innere Medizin

Lung Cancer Group Cologne (LCGC)
am Centrum für Integrierte Onkologie Köln Bonn

Kerpener Str. 62 | 50937 Köln

Tel.: 0221 478 87008

Fax: 0221 478 87010
E-Mail: lungenkrebs@uk-koeln.de

… mehr erfahren Sie hier!

  • © 2015 LungCancerGroupCologne
  • Sitemap
  • Contact
  • Imprint
  • Terms & Conditions
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress